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Cyclooxygenase (COX)catalyzes formation of prostaglandins thatcontribute tothe inﬂammationin atherosclerosis.Our objective
was to study whether the functional C variant of the −765G → C polymorphism in the human COX-2 gene associates with the
severity of coronary atherosclerosis measured at the coronary artery level. The Helsinki sudden death study autopsy material (n =
300) comprised of Finnish men who died suddenly. The area of atherosclerotic lesions in the coronary arteries was quantitated,
and coronary narrowing was measured. The occurrence of myocardial infarction (MI) was assessed. Genotyping was by restriction
endonuclease analysis. Men carrying the minor C allele had larger areas of complicated lesions (P = .024) and a higher number
of coronary arteries that had over 50% stenosis (P = .036) compared to men representing the common GG genotype. The COX-2
polymorphism was not associated with MI. Our data suggest that COX-2 may be involved in plaque growth.
Copyright © 2008 Kati H. Huuskonen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cyclooxygenase (COX) catalyzes the ﬁrst two steps in
prostanoid production from arachidonic acid to many
prostaglandins including prostacyclin and thromboxane.
The enzyme has three known isoforms. COX-1 is constitu-
tively expressed in most human tissues under basal condi-
tions. COX-2 expression is primarily induced in response to
inﬂammatory stimuli by growth factors, mitogens, and cy-
tokines [1]. COX-3 is a COX-1 derived isozyme. Its func-
tional role still remains poorly understood [2].
COX-2 levels are raised in chronic inﬂammatory dis-
eases including atherosclerosis. COX-2 expression has been
detected in endothelial cells, smooth muscle cells, mono-
cytes,andmacrophageswithinhumanatheroscleroticlesions
[3, 4]. Many prostaglandins produced by the COX-2 route
including thromboxane stimulate vasoconstriction, platelet
aggregation, and leukocyte-endothelial cell adhesion, which
all contribute to formation of atherosclerosis and thrombo-
sis [5–7]. However, the main prostaglandin produced by en-
dothelialcellsisprostacyclin(PGI2),whichactsasavasodila-
tor and inhibits platelet aggregation, leukocyte activation,
and adhesion [8].
A functional G→C polymorphism located 765 basepairs
upstream from the transcription start site (−765G→C) has
been identiﬁed in the human COX-2 gene with C allele lead-
ingtodecreasedpromoteractivityinvitro[9].Previousstud-
ies have shown that C allele might provide protective eﬀects
against clinical events, for example, myocardial infarction
(MI), stroke [10] and cerebrovascular ischemia [11]. C al-
lele may also be associated with lower levels of inﬂamma-
tory markers such as C-reactive protein and interleukin-6
in cardio/cerebrovascular and hypercholesterolemic patients
[9–12]. However, in contrast to these prior data, Hegener et
al. found no evidence for an association of the COX-2 poly-
morphisms/haplotypes neither with risk of incident MI nor2 Mediators of Inﬂammation
with ischemic stroke [13]. Furthermore, Kohsaka et al. have
recentlyreportedthattheCOX-2-765G→Cpo l ymo rp hi smi s
in fact a risk factor for incident stroke in African-Americans
[14].
The previous contradictory observations suggest that ad-
ditionalevaluationiswarrantedtoinvestigatetheassociation
between the COX-2 765G→C polymorphism and cardiovas-
cular disease. We have examined the association of this poly-
morphism with the risk of severity of atherosclerosis at the
coronary artery level in a previously collected autopsy se-
riesofageneticallyhomogeneouspopulationofFinnishmen
who had died suddenly out of hospital.
2. SUBJECTS AND METHODS
2.1. Subjects
HSDS was designed to investigate factors predisposing to
sudden death in Finnish middle-aged men living in Helsinki
and its environment [15]. The autopsy series was collected
during 12 months in 1991-1992 at the department of Foren-
sic Medicine in the University of Helsinki. The indica-
tions for autopsy were out-of-hospital death of a previously
healthy person, accidental death, suspected intoxication, sui-
cide, and death in connection with medical treatment. The
original study population comprised a prospective series of
300malesaged33–70years(mean53years).Thisautopsyse-
ries covered 28% of all deaths of males within this age group
in the area of Helsinki during the study period in question.
The cause of death was cardiac disease (coronary heart dis-
ease (CHD), cardiomyopathies, hypertrophy, or dilatation
of the heart) in 38.3% (n = 115), other diseases in 20.3%
(n = 61) and violent death (suicides and accidents) in 41.4%
(n = 124). Men with a coronary event (MI, AMI with coro-
nary thrombus, or coronary thrombus only) (n = 72) were
also compared with men with no coronary event (n = 228).
2.2. Measurementsofcoronaryarterydisease
At autopsy, coronary angiography was performed using vul-
canizing liquid silicone rubber mixed with lead oxide as con-
trast medium [16]. Proximal, middle, and distal narrowing
of the main trunks of the left anterior descending artery
(LAD), right coronary artery (RCA), and left circumﬂex
artery (LCX) was measured with a micrometer on the rubber
cast model. The percentage of coronary narrowing was ob-
tained by dividing the diameter (in millimeters) of the great-
est stenosis by that of the nearest proximal unaﬀected part of
the cast model of the same artery. Based on the presence of
over 50% stenosis in one, two, or three major coronary arter-
ies, the study population was divided into subgroups accord-
ing to number of diseased vessels.
The proximal parts of the LAD, LCX, and RCA were
dissected free, opened, and attached to a card and then
ﬁxed in 10% buﬀered formalin. The vessel wall was subse-
quently stained for fat by the Sudan IV method. The follow-
ingatheroscleroticchangeswereassessed:fattystreak,ﬁbrous
plaque, complicated lesion, and the area of calciﬁcation. Flat
orraisedintimallesionsthatweredistinctlystainedbySudan
IVanddidnotshowmorecomplexchangeswereclassiﬁedas
fatty streaks. An elevated lesion that did not display ulcera-
tion, haemorrhage, necrosis, or thrombosis was considered
as a ﬁbrous plaque. An area was regarded as complicated le-
sion, if it expressed one or several changes mentioned above,
with or without calcium deposit. The part of the aorta show-
ing intense X-ray-positive signal in the radiogram was con-
sideredasanareaofcalciﬁcation.Theareasofatherosclerotic
lesions and the total areas of coronary segments were evalu-
ated using the standard planimetric technique [15]. The pro-
portions of the divergent atheromatous changes were calcu-
lated based on the total surface area of the coronary arteries
[15]. The occurrence of MI in the series was conﬁrmed by a
macroscopic and histologic examination of the myocardium.
The presence of coronary thrombus was recorded during au-
topsy when coronary arteries were dissected longitudinally.
Autopsy and COX-2 genotype data were available in 300
cases, these comprising the ﬁnal study population.
2.3. Riskfactorsunderlyingcoronaryarterydisease
A spouse, relative, or a close friend of the deceased was in-
terviewed within 2 weeks following the autopsy. Besides the
questions pertaining to risk of sudden death (i.e., arterial hy-
pertension, diabetes), additional questions were included to
deﬁnethesmokinghabitsofthedeceased.Therelative/friend
wasaskedwhetherthepersonhadsmokedduringhislifeand
how many cigarettes he had smoked daily. Data on smok-
ing habits were obtained in 148 cases. In addition to COX-2
genotype and autopsy data, complete data on all risk factors
were available in 118 cases.
2.4. COX-2genotyping
The promoter region of the human COX-2 gene surround-
ing the site of −765G→Cp o l y m o r p h i s mw a sp o l y m e r a s e
chain reaction (PCR) ampliﬁed using DNAs extracted from
cardiac muscle as a template. Primers for DNA ampliﬁ-
cation were designed based on the published sequence
of the human COX-2 gene (NCBI/U04636, gi: 496975)
using the Primer3 software (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3 www.cgi). The 25 μl-reaction was
composed of 50pmol of each primer (TAG Copenhagen,
Copenhagen, Denmark) (forward 5 -CATTAACTATTT-
ACAGGGTAACTGCTT-3 ; reverse 5 -TGCAGCACATAC-
ATACATAGCTTTT-3 ), 200μMo fe a c hd N T Pa n d2 , 5 U
HotStarTaq DNA Polymerase in 1×PCR buﬀer (Qiagen,
Valencia, CA, USA). PCR conditions included 15 minutes
of initial polymerase activation step at 94◦Cf o l l o w e db y3 5
three-step cycles of denaturation at 94◦C for 30 seconds,
annealing at 56◦C for 30 seconds, extension at 72◦Cf o r3 0
seconds, and ﬁnal extension at 72◦Cf o r5m i n u t e s .
The primers generated fragments of 228bp which were
genotyped by SsiI (Fermentas, Vilnius, Lithuania) restric-
tion endonuclease. PCR product was cleaved into fragments
of 168bp and 60bp, if the G allele was present. Digested
products were resolved with 2% MetaPhor (Cambrex, East
Rutherford, NJ, USA) agarose gel electrophoresis and visual-
ized by ethidium bromide staining.Kati H. Huuskonen et al. 3
Table 1: Association of combined COX-2 genotypes with coronary atherosclerotic changes, number of main coronary arteries with stenosis
of over 50%, and myocardial infarction.
Genotype
GG GC + CC P value∗ P value†
All subjects n = 223 n = 77 n = 300 n = 118
Atherosclerotic changes (%)
Fatty streaks 9.91 ± 0.54 8.69 ±0.74 0.161 0.341
Fibrous plaques 5.79 ± 0.41 6.31 ±0.72 0.858 0.567
Calciﬁcations 3.78 ± 0.39 5.37 ±1.01 0.120 0.031
Complicated lesions 2.24 ± 0.37 4.15 ±1.25 0.024 0.017
Number of coronary arteries with stenosis of over 50% (0–3) 0.33 ± 0.67 0.58 ±0.93 0.036 0.008
Myocardial infarction 23.3% 26.0% 0.809 0.350
Subjects with coronary event n = 52 n = 20 n = 72 n = 35
Complicated lesions 6.81 ± 8.67 14.00 ±18.84 0.040 0.015
Number of coronary arteries with stenosis of over 50% (0–3) 1.00 ± 1.00 1.69 ±1.14 0.040 0.050
Subjects with no coronary event n = 172 n = 56 n = 228 n = 83
Complicated lesions 0.91 ± 2.85 0.88 ±1.55 0.876 0.541
Number of coronary arteries with stenosis of over 50% (0–3) 0.18 ± 0.46 0.20 ±0.40 0.884 0.990
Mean ± SE. ANCOVA ∗ adjusted by age and BMI, or † age, BMI, smoking, hypertension and diabetes.
2.5. Statisticalanalysis
Results were analyzed by SPSS for Windows software, ver-
sion 14.0 (SPSS, Chicago, IL, USA). Mean ± standard error
(SE) is reported for continuous variables. For normally dis-
tributed continuous variables, one-way-ANCOVA was used
with age, body mass index (BMI), smoking status (yes/no),
hypertension (yes/no), and diabetes (yes/no) as covariates.
Since variables measuring atherosclerotic changes were not
normally distributed, logarithmic transformations were uti-
lizedforvaluesoffattystreaks,ﬁbrousplaques,calciﬁcations,
and complicated lesions, but results are displayed in crude
form.
3. RESULTS
In the study population, COX-2 genotype frequencies were
GG 74.4%, GC 24.3%, and CC 1.3%. Since there were only
four cases representing the CC genotype, men carrying the C
allele were pooled together as one group for statistical analy-
ses.
Men carrying the C allele had signiﬁcantly larger areas of
complicated lesions in their coronary arteries than the men
with GG genotype (P = .024) with adjustment for age and
BMI. After further adjustment with smoking, hypertension,
anddiabetes,therewasasigniﬁcantdiﬀerencebetweengeno-
types and calciﬁcations (P = .031) and genotypes and com-
plicated lesions (P = .017) (Table 1, Figure 1). No signiﬁcant
diﬀerences existed between COX-2 genotypes and the areas
of ﬁbrous plaques or fatty streaks. The C allele carriers had a
highernumberofover50%stenosisinone,two,orthreema-
jor coronary arteries (P = .036) compared to those with the
GG genotype, with adjustment for age and BMI. After fur-
ther adjustment with smoking, hypertension, and diabetes,
this diﬀerence was even more signiﬁcant (P = .008) (Table 1,
Figure 1). There was no statistically signiﬁcant association
between genotype and occurrence of MI (acute, old, or any
MI) by age, BMI, smoking, hypertension, and diabetes as co-
variates (Table 1).
Men with a coronary event (MI, AMI with coronary
thrombus, or coronary thrombus only) (n = 72) were also
compared with men with no coronary event (n = 228). In the
coronary event group, men carrying the C allele had signif-
icantly larger areas of complicated lesions in their coronary
arteries than the men with GG genotype with adjustment for
age and BMI (P = .040) and after further adjustment with
smoking, hypertension, and diabetes (P = .015). Also in the
coronaryeventgroup,theCallelecarriershadahighernum-
berofover50%stenosisinone,two,orthreemajorcoronary
arteries compared to those with the GG genotype, with ad-
justment for age and BMI (P = .040) and after further adjust-
ment with smoking, hypertension, and diabetes (P = .050)
(Table 1). No signiﬁcant diﬀerences existed between COX-2
genotypes and the areas of ﬁbrous plaques or fatty streaks in
the coronary event group (data not shown). The genotypes
did not diﬀer in the group with no coronary event (Table 1).
4. DISCUSSION
The results of this study propose that middle-aged Finnish
men with sudden death that carried the rare C allele of the
COX-2 765G→C polymorphism had more often advanced
coronary plaques, characterized by more extensive areas of
complicated lesions, compared to men with the GG geno-
type. This association was most pronounced in subjects with
a coronary event. Variation in COX-2 promoter genotype
showed no association with early coronary atherosclerosis
characterized by fatty streaks and ﬁbrous plaques. A previ-
ous study has shown that the 765G→C allele might provide
protective eﬀects against myocardial infarction [10]. C al-
lele may also be associated with lower levels of inﬂamma-
tory markers such as C-reactive protein and interleukin-64 Mediators of Inﬂammation
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Figure 1: Association of COX-2 genotype with atherosclerotic changes. P values are from ANCOVA with age and BMI as covariates. Error
bars represent SE.
in cardio/cerebrovascular and hypercholesterolemic patients
[9, 12]. In contrast to these prior data, Hegener et al. found
noevidenceforanassociationofthepolymorphismwithrisk
of incident MI [13]. Furthermore, Kohsaka et al. have re-
cently reported that the 765G→C allele is in fact a risk fac-
tor for incident stroke in African-Americans [14]. We did
not observe an association of this polymorphism on MI, but
a larger sample size than our material is needed to resolve
the question. Nevertheless, our observations of complicated
atherosclerosis at the coronary artery level suggest that the
765G→C allele is in fact a risk factor for coronary disease. A
major limitation of our study was that there were only 118
subjects with complete data on risk factors underlying coro-
nary artery disease. However, this further statistical adjust-
ment strengthened rather than weakened our ﬁndings on the
original 300 men, adjusted for age and BMI. Nevertheless, a
study on a larger sample is necessary to conﬁrm the results of
the present investigation.
Men carrying the C allele had a higher number of coro-
nary arteries that had over 50% stenosis, compared to men
who were GG homozygous. In contrast, the relation be-
tween the C allele and severity of atherosclerosis has previ-
ously been studied at the coronary level by angiography in
an Italian population, but no association was found [10].
The polymorphism under study seems to be relatively rare
in the Finnish population with frequencies of GG 74.4%, GC
24.3%, and CC 1.3% whereas in the Italian population fre-
quencies are GG 50.7%, GC 43.3%, and CC 6.4% [10].
Theﬁndingthatstenosiswasmoreoftenobservedinmen
possessing C allele than in men representing GG genotype
may provide support for the hypothesis that C allele may
lead to more extensive plaque growth. In fact, since the C
allele leads to decreased promoter activity [9], it could con-
tribute to lower-prostaglandin production. Matrix metallo-
proteinases (MMPs) and the extracellular matrix (ECM) de-
grading enzymes are partly up regulated by PGE2 which isKati H. Huuskonen et al. 5
generated through COX-2 route. As a consequence of di-
minished PGE2 biosynthesis, a decrease in MMP-9 expres-
sion could follow [17] and lead to accumulation of extra-
cellular matrix by smooth muscle cells. In line with our re-
sults, Cipollone et al. [10] reported that in carotid plaques
of C allele carriers there is more interstitial collagen com-
pared to plaques of GG homozygotes which could contribute
to plaque growth [18, 19].
In conclusion, the rare COX-2 gene C allele associated
with complicated plaques and severe stenosis at the coronary
artery level. This suggests that COX-2 may be involved in
plaque growth. No protective eﬀect against MI was seen.
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